Komori
Kirin Holdings (2503) · InitiativeFirst stated

Development discontinued for KHK4083 (rocatinlimab)

First written in FY2026-H1. . Latest entry: FY2026-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Development discontinued for KHK4083 (rocatinlimab)A theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026-H1First statedAnnual report

    「事業利益は、売上収益の増加に伴う売上総利益の拡大に加え、rocatinlimabの開発中止に伴う研究開発費の減少及び円安方向の為替変動の影響により、増益となりました。」

    KHK4083/rocatinlimabの開発中止が初めて記載された。開発中止に伴い研究開発費が減少し、医薬事業の事業利益の増益要因となった。また、臨床試験中止に伴うクロージングコストを含む契約損失203億57百万円も計上された。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Kirin Holdings's next results are scheduled for 2026-11-11. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.